Table 1. General characteristics.
| PedSjDn=19 | Diagnostic adSjDn=32 | PedSjD versus diagnostic adSjDP value | Trial adSjDn=42 | PedSjD versus trial adSjDP value | ||||
| Gender, female, n (%) | 15 (78.9) | 31 (96.9) | 0.58 | 38 (90.5) | 0.24 | |||
| Age at start symptoms, years* | 9 (9–12) | 45 (30–58) | 0.001 | 44 (30–56) | 0.001 | |||
| Age at biopsy, years* | 14 (10–17) | 52 (46–63) | 0.001 | 51 (39–61) | 0.001 | |||
| Duration of symptoms at moment of biopsy, years* | 3 (2–5) | 5 (3–13) | 0.024 | 4 (2–8) | 0.07 | |||
| Fulfilment of ACR/EULAR criteria, n (%) | 16 (84) | 32 (100) | 0.022 | 40 (95) | 0.15 | |||
| ESSDAI total score, range* | 5 (3–11) | 4 (2–12) | 0.54 | 11 (8–16) | 0.001 | |||
| ESSDAI score glandular, range domain* | 2 (2–4) | 0 (0–2) | 0.001 | 1 (1–2) | 0.001 | |||
| ESSDAI glandular domain positive, n (%) | 18 (94.7) | 12 (37.5) | <0.001 | 33 (78.6) | 0.117 | |||
| Ultrasound | ||||||||
| Hocevar score total, range* | 23 (13–29)† | 16 (9–24)† | 0.28 | 16 (11–29)‡ | 0.33 | |||
| Hocevar score parotis, range* | 10 (8–16)† | 8 (4–12)† | 0.24 | 8 (4–14)‡ | 0.38 | |||
| Hocevar score percentage parotis/total score* | 52 (48–55)† | 52 (36–57)† | 0.82 | 50 (38–58)‡ | 0.78 | |||
| OMERACT score total* | 8 (5–10)† | 6 (1.5–8)† | 0.74 | 6 (3–11)‡ | 0.35 | |||
| Salivary flow rates | ||||||||
| UWS value, mL/min* | 0.18 (0.05–0.55)§ | 0.09 (0.03–0.19) | 0.041 | 0.10 (0.02–0.18) | 0.046 | |||
| UWS <0.1 mL/min, n (%) | 7 (38.9)§ | 19 (59.4) | 0.16 | 23 (54.8) | 0.26 | |||
| SWS value, mL/min* | 0.4 (0.22–0.59)§ | 0.65 (0.34–0.94) | 0.98 | 0.26 (0.11–0.45) | 0.033 | |||
| Medication use, n (%) | Current | History | Current | History | Current | History | ||
| Hydroxychloroquine | 5 (26) | 7 (37) | 3 (9) | 12 (38) | 1 (2) | 11 (26) | ||
| tDMARD | 1 (5) | 0 (0) | 3 (9) | 8 (25) | 0 (0) | 7 (17) | ||
| Corticosteroids | 1 (5) | 2 (11) | 3 (9) | 1 (3) | 0 (0) | 6 (14) | ||
Significant p values are italicised and bold.
*Data are reported as median (IQR) or n (%).
§Missing data: 0–5; †Missing data: 6–10; ‡Missing data: 11–15
ACR/EULARAmerican College of Rheumatology/EULARadSjDadult-onset Sjögren’s diseaseESSDAIEULAR Sjogren’s Syndrome Disease Activity IndexNSAIDnon-steroidal anti-inflammatory drugOMERACT scoreOutcome Measures in Rheumatolgy ultrasound scorePedSjDpaediatric-onset Sjögren’s diseaseSWSstimulated whole salivatDMARDtraditional disease-modifying antirheumatic drugUWSunstimulated whole saliva